CCIA
DCPH

Campbell & Co Investment Adviser’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Campbell & Co Investment Adviser’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50,735
Closed -$818K – 1424
2023
Q4 		$818K Buy
+50,735
New +$647K 0.07% 475
2023
Q2 		– Sell
-42,881
Closed -$663K – 1178
2023
Q1 		$663K Buy
42,881
+14,664
+52% +$245K 0.12% 305
2022
Q4 		$462K Buy
+28,217
New +$459K 0.11% 348

Other funds holding DCPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Campbell & Co Investment Adviser's DCPH Position: Q1 2024 in Review

Campbell & Co Investment Adviser sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2024, closing a stake of 50,735 shares — an estimated $818K sold.

Campbell & Co Investment Adviser first reported a position in DCPH in Q4 2022 and held it in 3 quarters. The position peaked at $818K in Q4 2023. 177 funds tracked by Wall St. Rank hold DCPH as of Q1 2024.

  • Campbell & Co Investment Adviser reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 50,735 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $818K.
  • Campbell & Co Investment Adviser first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $818K in Q4 2023.
  • 177 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2024, filed 10 May 2024.